Iron supplementation in pregnancy - Does the preparation matter?

被引：37
作者：
Melamed N. [1 ,2 ]
Ben-Haroush A. [1 ,2 ]
Kaplan B. [1 ,2 ]
Yogev Y. [1 ,2 ]
机构：
[1] Department of Obstetrics and Gynecology, Helen Schneider Hospital for Women, Rabin Medical Center
[2] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv
来源：
Archives of Gynecology and Obstetrics | 2007年 / 276卷 / 6期
关键词：
Compliance; Iron; Pregnancy; Preparation; Supplementation;
D O I：
10.1007/s00404-007-0388-3
中图分类号：
学科分类号：
摘要：
Objective: To assess the use, side effects and discontinuation rates of iron preparations during pregnancy. Design: Six hundred and twelve randomly selected postpartum women completed a questionnaire on iron supplement use in the second and third trimesters. Results: Of the 517 women (84.5%) reported using iron supplements, 453 were eligible for the study. The most common preparation was ferrous fumarate (46.8%, P < 0.01), followed by ferrous sulfate (31.8%), ferric polymaltose (12.4%), and ferric bisglycinate (7.3%). Almost half the participants (45%) reported at least one adverse effect, especially constipation (27.4%, P < 0.01), nausea (10.8%). Multivitamin preparations and ferric bisglycinate were associated with the fewest side effects (23.7, 21.2% respectively, P < 0.01), and ferrous fumarate and immediate-release ferrous sulfate with the most (56.3, 53.7% respectively). Eighty-three women discontinued their originally prescribed iron preparation, mainly (89%) due to side effects. Discontinuation rates were lowest for the multivitamin and ferric bisglycinate (10.5, 9.1%, respectively). In most cases, the specific preparation was recommended by the women's physician (76%). Conclusion: Ferrous fumarate-containing multivitamin preparations and ferric bisglycinate, although infrequently recommended as the first-line of iron supplementation, may be associated with less side effects and better compliance. © 2007 Springer-Verlag.
引用
收藏
页码：601 / 604
页数：3
相关论文
共 26 条
[1]  
The Prevalence of Anaemia in Women: A Tabulation of Available Information, (1992)
[2]  
MacGregor M., Maternal anaemia as a factor in prematurity and perinatal mortality., Scott Med J, 8, (1963)
[3]  
Scholl T.O., Hediger M.L., Anemia and iron-deficiency anemia: Compilation of data on pregnancy outcome (discussion 500S-501S)., Am J Clin Nutr, 59, (1994)
[4]  
Levy A., Fraser D., Katz M., Mazor M., Sheiner E., Maternal anemia during pregnancy is an independent risk factor for low birthweight and preterm delivery, Eur J Obstet Gynecol Reprod Biol, 122, pp. 182-186, (2005)
[5]  
Stoltzfus R.D., Dreyfuss M.L., Guidelines for the Use of Iron Supplements to Prevent and Treat Iron Deficiency Anemia, (2000)
[6]  
Pena-Rosas J.P., Viteri F.E., Effects of routine oral iron supplementation with or without folic acid for women during pregnancy, Cochrane Database Syst Rev, 3, (2006)
[7]  
Casanueva E., Viteri F.E., Mares-Galindo M., Meza-Camacho C., Loria A., Schnaas L., Et al., Weekly iron as a safe alternative to daily supplementation for nonanemic pregnant women, Arch Med Res, 37, pp. 674-682, (2006)
[8]  
Hemminki E., Merilainen J., Long-term follow-up of mothers and their infants in a randomized trial on iron prophylaxis during pregnancy, Am J Obstet Gynecol, 173, pp. 205-209, (1995)
[9]  
Schultink W., Van Der Ree M., Matulessi P., Gross R., Low compliance with an iron-supplementation program: A study among pregnant women in Jakarta, Indonesia, Am J Clin Nutr, 57, pp. 135-139, (1993)
[10]  
Nordeng H., Eskild A., Nesheim B.I., Aursnes I., Jacobsen G., Guidelines for iron supplementation in pregnancy: Compliance among 431 parous Scandinavian women, Eur J Clin Pharmacol, 59, pp. 163-168, (2003)
123